{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:34:59Z","timestamp":1789457699501,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ygyno.2014.07.083","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T19:31:04Z","timestamp":1405107064000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study"],"prefix":"10.1016","volume":"135","author":[{"given":"Matthew A.","family":"Powell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Jeske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique A.","family":"Spillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela M.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.07.083_bb0005","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cncr.24160","article-title":"Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time","volume":"115","author":"Wright","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0010","first-page":"9","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2014.07.083_bb0015","first-page":"S2","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0030","doi-asserted-by":"crossref","first-page":"399s","DOI":"10.1200\/jco.2010.28.15_suppl.5038","article-title":"A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia","volume":"28","author":"Correa","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2010.01.013","article-title":"A phase II study of sorafenib in advanced uterine carcinoma\/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia","volume":"117","author":"Nimeiri","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0040","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0045","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2007.15.8808","article-title":"Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2007.03.006","article-title":"Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer","volume":"106","author":"Albitar","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2013.02.019","article-title":"A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study","volume":"129","author":"Leslie","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0060","first-page":"S1","article-title":"Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0070","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0075","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0080","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2013.59","article-title":"Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial","volume":"108","author":"Colombo","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0085","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0100","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0105","doi-asserted-by":"crossref","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0110","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0115","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/modpathol.2011.110","article-title":"FGFR2 alterations in endometrial carcinoma","volume":"24","author":"Gatius","year":"2011","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.07.083_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0125","doi-asserted-by":"crossref","first-page":"e52795","DOI":"10.1371\/journal.pone.0052795","article-title":"High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated","volume":"7","author":"Krakstad","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jmoldx.2011.04.003","article-title":"Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry","volume":"13","author":"Beadling","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0135","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1158\/0008-5472.CAN-08-0770","article-title":"Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation","volume":"68","author":"Byron","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0140","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0145","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0150","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0155","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","article-title":"Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma","volume":"18","author":"Finn","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0160","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-10-2011","article-title":"Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Park","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0170","first-page":"427","article-title":"A network algorithm for performing Fisher exact test in R\u00d7C contingency-tables","volume":"78","author":"Mehta","year":"1983","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0175","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PPO.0b013e318212db3c","article-title":"Molecular predictors of response to antiangiogenesis therapies","volume":"17","author":"Gerger","year":"2011","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-005-9157-9","article-title":"Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density","volume":"98","author":"Tsutsui","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0185","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1073\/pnas.172161899","article-title":"Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo","volume":"99","author":"Lobov","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2004.11.004","article-title":"Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage\/dysfunction and atherosclerosis","volume":"180","author":"Lim","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.ygyno.2014.07.083_bb0200","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814011585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814011585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:36:17Z","timestamp":1758771377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814011585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0090825814011585"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.083","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718491022.793527266","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}